Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant injection for prevention of postoperative nausea and vomiting in breast cancer surgery
ChiCTR2500113173Phase 4Completed
- Sponsor
- Shanxi Cancer Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoint: Complete response rate (CR). Started Nov 2025; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2500113173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113173.